SecBot SecBot

NSRX

Nasus Pharma Ltd
NYSE· Pharmaceutical Preparations· Inc. L3· CIK 0002029039 Biotech & Drug Discovery
$3.53 +0.04 (+1.00%)
Oct 26 4:00 PM ET · prev $3.49
Market cap
$37.8M
Nano cap
Median target
$19.00
+439% · range $18.00–22.00
1 year
−55.7%
from $7.95 · Oct 27
30 days
−1.8%
from $3.59
52-week range
$2.01–9.15
−61% from high · low Mar 30
Avg volume 20D
22.8K
shares / day
Short interest
78.2K
≈0.7% of shares · −2.9%
Days to cover
2.9
at average volume
Insider net
+$61.8K
1 buyer · 0 sellers · 12 mo
New fund stakes
0
Q2 2026 13F · 0 exits
Filing reports
14
analyzed by SecBot
SecBot read MIXED 9 reports · 90 days
Balance 1 bearish · 1 bullish · 7 neutral oldest → newest, height = score
Avg score ·High conf. 7/9
Strongest BULLISH Nasus Pharma announced FDA clearance of its IND application for NS002, an intranasal epinephrine powder for…
All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

Signal stack

Where each data set points today.

  • InsidersBULLISH

    1 insider bought $61.8K at an average $2.53. No open-market sales. Price is 39% above their cost.

  • InstitutionsMIXED

    Q2 2026: 0 added (0 new), 1 trimmed or exited.

  • EstimatesRISING

    Current-quarter EPS estimate −$0.215 → $0.000 over 90 days. 2 up, 0 down in 30 days.

  • Short sellersSTEADY

    Short interest −2.9% to 78.2K shares. 2.9 days to cover, ≈0.7% of shares.

  • TrendDOWNTREND

    3% below its 50-day average.

Who's buying

13F· Q2 2026
0
new positions
0
exits
FundMoveSharesValue
MORGAN STANLEYTRIM1,000$3.5K

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

last action Mar 2026
12-month targets · 3 analysts

Price is below the lowest target. Median implies +439%.Targets as of Oct 26, 2026.

Recent actions
DateFirmActionRating
Mar 26, 2026Citizens
MAINTAIN
MAINTAINMarket Outperform
Dec 18, 2025Citizens
INITIATE
INITIATEMarket Outperform
Sep 29, 2025Laidlaw & Co.
INITIATE
INITIATEBuy
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Recent
Sep 9, 2026
Trading halt
Halt Resumed: NSRX — trading resumed after M (Volatility Trading Pause)
Halted 2026-09-09T15:11:00.000Z | Resumed 2026-09-09T15:21:00.000Z
Sep 9, 2026
Trading halt
Trading Halt: NSRX — M (Volatility Trading Pause)
Nasus Pharma Ltd. Ordinary Shares | Market: AMEX | Code: M — Volatility Trading Pause
Sep 8, 2026
Press release
Nasus Pharma to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
TEL AVIV, Israel, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Nasus Pharma Ltd. (NYSE: NSRX) ("Nasus", “Nasus Pharma” or the "Company"), a clinical-stage…
Sep 1, 2026
Trading halt
Halt Resumed: NSRX — trading resumed after M (Volatility Trading Pause)
Halted 2026-09-01T16:15:09.000Z | Resumed 2026-09-01T16:20:09.000Z
Sep 1, 2026
Trading halt
Trading Halt: NSRX — M (Volatility Trading Pause)
Nasus Pharma Ltd. Ordinary Shares | Market: AMEX | Code: M — Volatility Trading Pause

Insider ledger

Form 4
$61.8K
bought · 1 insider
$0
sold · 0 insiders
+39.4%
vs their $2.53 cost
DateInsiderTypeValue
Jun 17, 2026
Teleman Dan Benjamin
Chief Executive Officer
BUY$20.3K
Apr 22, 2026
Teleman Dan Benjamin
Chief Executive Officer
BUY$10.9K
Mar 31, 2026
Teleman Dan Benjamin
Chief Executive Officer
BUY$30.6K

Earnings setup

Estimates
$0.00
EPS estimate, this quarter
+100%
estimate change, 90 days
2↑ 0↓
revisions, 30 days
Current-quarter EPS estimate
PeriodEPS est.Range30D rev.Revenue
Current Q$0.00$0.00–$0.00—$0.00
Next Q-$0.58-$0.73–-$0.31+0.0%$0.00
Current FY-$1.13-$1.28–-$0.84+0.0%$0.00
Next FY-$1.13-$1.46–-$0.81+0.0%$0.00

Short side

FINRA· Sep 30, 2026
78,238
shares short
-2.9%
vs prior settlement
2.9
days to cover
≈0.7%
of shares outstanding
Trading halts
Sep 9, 2026Volatility PauseResumed
Sep 1, 2026Volatility PauseResumed
Aug 4, 2026Volatility PauseResumed
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Oct 8, 2026 SEC
Nasus Pharma held its Annual and Special General Meeting of Shareholders on October 8, 2026. All agenda items were…
6-K — Impact 2/10
Sep 23, 2026 SEC
Analysis based on filing metadata only — document content was unavailable. This is a Form 3 (initial statement of…
3 — Impact 1/10
Sep 18, 2026 SEC
Nasus Pharma filed a prospectus supplement for an at-the-market (ATM) offering of up to $8.5 million of ordinary…
424B5 — Impact 5/10
Sep 9, 2026 Trading halt
Halt Resumed: NSRX — trading resumed after M (Volatility Trading Pause)
Halted 2026-09-09T15:11:00.000Z | Resumed 2026-09-09T15:21:00.000Z
Jun 30, 2026 Inst.
MORGAN STANLEY — TRIM
1,000 shares ($3.5K)
Jun 17, 2026 Insider
Teleman Dan Benjamin bought 6,550 shares
Chief Executive Officer @ $3.10 ($20.3K)
Apr 22, 2026 Insider
Teleman Dan Benjamin bought 2,900 shares
Chief Executive Officer @ $3.76 ($10.9K)
Mar 31, 2026 Insider
Teleman Dan Benjamin bought 15,000 shares
Chief Executive Officer @ $2.04 ($30.6K)

SecBot reports

14 filings · 2 press releases · 1 bullish · 3 bearish · 10 neutral
All NSRX filing & press-release reports (16)